A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

por Naing, Aung, Gainor, Justin F, Gelderblom, Hans, Forde, Patrick M, Butler, Marcus O, Lin, Chia-Chi, Sharma, Sunil, Ochoa de Olza, Maria, Varga, Andrea, Taylor, Matthew, Schellens, Jan H M, Wu, Hongqian, Sun, Haiying, Silva, Antonio P, Faris, Jason, Mataraza, Jennifer, Cameron, Scott, Bauer, Todd M
Publicado 2020